32284 Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices 

Blanton, M.D., 43 FR 27,616, 27,617 

(1978). 

This rule derives from the text of two 

provisions of the CSA. First, Congress 

defined the term ‘‘practitioner’’ to mean 

‘‘a physician . . . or other person 

licensed, registered, or otherwise 

permitted, by . . . the jurisdiction in 

which he practices . . . , to distribute, 

dispense, . . . [or] administer . . . a 

controlled substance in the course of 

professional practice.’’ 21 U.S.C. 

802(21). Second, in setting the 

requirements for obtaining a 

practitioner’s registration, Congress 

directed that ‘‘[t]he Attorney General 

shall register practitioners . . . if the 

applicant is authorized to dispense . . . 

controlled substances under the laws of 

the State in which he practices.’’ 21 

U.S.C. 823(f). Because Congress has 

clearly mandated that a practitioner 

possess state authority in order to be 

deemed a practitioner under the CSA, 

the DEA has held repeatedly that 

revocation of a practitioner’s registration 

is the appropriate sanction whenever he 

is no longer authorized to dispense 

controlled substances under the laws of 

the state in which he practices. See, e.g., 

James L. Hooper, 76 FR at 71,371–72; 

Sheran Arden Yeates, M.D., 71 FR 

39,130, 39,131 (2006); Dominick A. 

Ricci, M.D., 58 FR 51,104, 51,105 (1993); 

Bobby Watts, M.D., 53 FR 11,919, 11,920 

(1988); Frederick Marsh Blanton, 43 FR 

at 27,617. 

Under Nebraska law, ‘‘[d]ispense 

means to deliver a controlled substance 

to an ultimate user or a research subject 

pursuant to a medical order issued by a 

practitioner authorized to prescribe, 

including the packaging, labeling, or 

compounding necessary to prepare the 

controlled substance for such delivery.’’ 

Neb. Rev. Stat. § 28–401(8) (Westlaw, 

Current through legislation effective 

May 6, 2021). Further, ‘‘[p]ractitioner 

means a physician . . . or any other 

person licensed, registered, or otherwise 

permitted to distribute, dispense, 

prescribe, conduct research with respect 

to, or administer a controlled substance 

in the course of practice or research in 

this state . . . .’’ Id. at § 28–401(21). 

Because Registrant is not currently 

licensed as a physician, or otherwise 

licensed, in Nebraska, he is not 

authorized to dispense controlled 

substances in Nebraska. 

Here, the undisputed evidence in the 

record is that Registrant currently lacks 

authority to practice medicine in 

Nebraska. As already discussed, a 

physician must be a licensed 

practitioner to dispense a controlled 

substance in Nebraska. Thus, because 

Registrant lacks authority to practice 

medicine in Nebraska and, therefore, is 

not authorized to handle controlled 

substances in Nebraska, Registrant is not 

eligible to maintain a DEA registration. 

Accordingly, I will order that 

Registrant’s DEA registration be 

revoked. 

Order 

Pursuant to 28 CFR 0.100(b) and the 

authority vested in me by 21 U.S.C. 

824(a), I hereby revoke DEA Certificate 

of Registration No. FK4149882 issued to 

Tareq A. Khedir Al-Tiae, M.D. Further, 

pursuant to 28 CFR 0.100(b) and the 

authority vested in me by 21 U.S.C. 

823(f), I hereby deny any pending 

application of Tareq A. Khedir Al-Tiae, 

M.D., to renew or modify this 

registration, as well as any other 

pending application of Tareq A. Khedir 

Al-Tiae M.D., for additional registration 

in Nebraska. This Order is effective July 

19, 2021. 

D. Christopher Evans, 

Acting Administrator. 

[FR Doc. 2021–12755 Filed 6–16–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–852] 

Bulk Manufacturer of Controlled 

Substances Application: AMPAC Fine 

Chemicals Virginia, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: AMPAC Fine Chemicals 

Virginia, LLC. has applied to be 

registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 16, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 16, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on May 5, 2021, AMPAC 

Fine Chemicals Virginia, LLC., 2820 

North Normandy Drive, Petersburg, 

Virginia 23805–2380, applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Methylphenidate ........... 1724 II 

Levomethorphan ........... 9210 II 

Levorphanol .................. 9220 II 

Morphine ....................... 9300 II 

Thebaine ....................... 9333 II 

Noroxymorphone .......... 9668 II 

Tapentadol .................... 9780 II 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. The company plans to 

manufacture the above-listed controlled 

substances in bulk for distribution to its 

customers. No other activities for these 

drug codes are authorized for this 

registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–12812 Filed 6–16–21; 8:45 am] 

BILLING CODE P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (21–035)] 

Notice of Intent To Grant an Exclusive, 

Co-Exclusive or Partially Exclusive 

Patent License 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of intent to grant 

exclusive, co-exclusive or partially 

exclusive patent license. 

SUMMARY: NASA hereby gives notice of 

its intent to grant an exclusive, coexclusive or partially exclusive patent 

license to practice the inventions 

described and claimed in the patents 

and/or patent applications listed in 

SUPPLEMENTARY INFORMATION below. 

DATES: The prospective exclusive, coexclusive or partially exclusive license 

may be granted unless NASA receives 

written objections including evidence 

and argument, no later than July 2, 2021 

that establish that the grant of the 

license would not be consistent with the 

requirements regarding the licensing of 

federally owned inventions as set forth 

in the Bayh-Dole Act and implementing 

regulations. Competing applications 

completed and received by NASA no 

later than July 2, 2021 will also be 

treated as objections to the grant of the 

contemplated exclusive, co-exclusive or 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices 32285 

partially exclusive license. Objections 

submitted in response to this notice will 

not be made available to the public for 

inspection and, to the extent permitted 

by law, will not be released under the 

Freedom of Information Act. 

FOR FURTHER INFORMATION CONTACT: 

Written objections relating to the 

prospective license or requests for 

further information may be submitted to 

Agency Counsel for Intellectual 

Property, NASA Headquarters at Email: 

hq-patentoffice@mail.nasa.gov. 

Questions may be directed to Helen 

Galus at (202) 358–3437. 

SUPPLEMENTARY INFORMATION: NASA 

intends to grant an exclusive, coexclusive, or partially exclusive patent 

license in the United States to practice 

the inventions described and claimed 

in: US 8,735,116 B2, High-Density Spot 

Seeding for Tissue Model Formation 

and US 9,243,223 B2, High-Density Spot 

Seeding for Tissue Model Formation to 

BSK Health Partners, LLC. having its 

principal place of business in North 

Richland Hills, Texas. The fields of use 

may be limited. NASA has not yet made 

a final determination to grant the 

requested license and may deny the 

requested license even if no objections 

are submitted within the comment 

period. 

This notice of intent to grant an 

exclusive, co-exclusive or partially 

exclusive patent license is issued in 

accordance with 35 U.S.C. 209(e) and 37 

CFR 404.7(a)(1)(i). The patent rights in 

these inventions have been assigned to 

the United States of America as 

represented by the Administrator of the 

National Aeronautics and Space 

Administration. The prospective license 

will comply with the requirements of 35 

U.S.C. 209 and 37 CFR 404.7. 

Information about other NASA 

inventions available for licensing can be 

found online at http://

technology.nasa.gov. 

Helen M. Galus, 

Agency Counsel for Intellectual Property. 

[FR Doc. 2021–12756 Filed 6–16–21; 8:45 am] 

BILLING CODE 7510–13–P 

NUCLEAR REGULATORY 

COMMISSION 

Advisory Committee on the Medical 

Uses of Isotopes: Meeting Notice 

AGENCY: U.S. Nuclear Regulatory 

Commission. 

ACTION: Notice of meeting. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) will convene a 

public teleconference meeting of the 

Advisory Committee on the Medical 

Uses of Isotopes (ACMUI) on July 15, 

2021, to discuss the ACMUI 

Subcommittee on Extravasations and 

Medical Event Reporting draft report on 

the NRC staff’s preliminary evaluation 

of whether extravasations merits a 

change in medical event reporting. The 

meeting agenda is subject to change. 

Meeting information, including a copy 

of the agenda and related documents, 

will be available on the ACMUI’s 

Meetings and Related Documents web 

page at https://www.nrc.gov/reading-rm/ 

doc-collections/acmui/meetings/ 

2021.html. The agenda and related 

meeting documents may also be 

obtained by contacting Ms. Kellee 

Jamerson using the information below. 

DATES: The teleconference meeting will 

be held on Thursday, July 15, 2021, 1:00 

p.m. to 3:00 p.m. Eastern Daylight Time. 

Date Webinar information 

July 15, 2021 .... Link: https://

usnrc.webex.com. 

Event number: 199 085 

4780. 

Public Participation: The meeting will 

also be held as a webinar. Any member 

of the public who wishes to participate 

in any portion of this meeting should 

register in advance of the meeting by 

accessing the provided link and event 

number above. Upon successful 

registration, an email confirmation will 

be generated providing the telephone 

bridge line and a link to join the 

webinar on the day of the meeting. 

Members of the public should also 

monitor the NRC’s Public Meeting 

Schedule at https://www.nrc.gov/pmns/ 

mtg for any meeting updates. If there are 

any questions regarding the meeting, 

please contact Ms. Jamerson using the 

information below. 

Contact Information: Kellee Jamerson, 

email: Kellee.Jamerson@nrc.gov, 

telephone: 301–415–7408. 

Conduct of the Meeting 

The ACMUI Chair, Darlene F. Metter, 

M.D., will preside over the meeting. Dr. 

Metter will conduct the meeting in a 

manner that will facilitate the orderly 

conduct of business. The following 

procedures apply to public participation 

in the meeting: 

1. Persons who wish to provide a 

written statement should submit an 

electronic copy to Ms. Jamerson at the 

contact information listed above. All 

written statements must be received by 

July 12, 2021, three business days prior 

to the meeting, and must pertain to the 

topics on the agenda for the meeting. 

2. Questions and comments from 

members of the public will be permitted 

during the meeting, at the discretion of 

the ACMUI Chairman. 

3. The draft transcript and meeting 

summary will be available on ACMUI’s 

website https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/ 

2021.html on or about August 31, 2021. 

4. Persons who require special 

services, such as those for the hearing 

impaired, should notify Ms. Jamerson of 

their planned participation. 

This meeting will be held in 

accordance with the Atomic Energy Act 

of 1954, as amended (primarily Section 

161a); the Federal Advisory Committee 

Act (5 U.S.C. App); and the 

Commission’s regulations in 10 CFR 

part 7. 

Dated at Rockville, Maryland this 14th day 

of June, 2021. 

For the U.S. Nuclear Regulatory 

Commission. 

Russell E. Chazell, 

Federal Advisory Committee Management 

Officer. 

[FR Doc. 2021–12767 Filed 6–16–21; 8:45 am] 

BILLING CODE 7590–01–P 

NUCLEAR REGULATORY 

COMMISSION 

[Docket No. 40–8907; NRC–2019–0026] 

United Nuclear Corporation Church 

Rock Project 

AGENCY: Nuclear Regulatory 

Commission. 

ACTION: Draft environmental impact 

statement; reopening of comment 

period. 

SUMMARY: On November 13, 2020, the 

U.S. Nuclear Regulatory Commission 

(NRC) issued for public comment a draft 

Environmental Impact Statement (EIS) 

for United Nuclear Corporation’s (UNC) 

license amendment request. The public 

comment period closed on May 27, 

2021. The NRC has decided to re-open 

the public comment period to allow 

more time for members of the public to 

develop and submit their comments. 

UNC is requesting authorization to 

amend its license (SUA–1475) to 

excavate approximately 1 million cubic 

yards (CY) of mine waste from the 

Northeast Church Rock Mine Site and 

dispose of it at the existing mill site in 

McKinley County, New Mexico. The 

NRC plans to hold a public meeting in 

the future to promote full understanding 

of the contemplated action and facilitate 

public comment. 

DATES: The comment period for the 

document published on November 13, 


lotter on DSK11XQN23PROD with NOTICES1